G. Krähn‐Senftleben

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a multicentre, randomized, observer-blind phase III study in comparison with a registered methyl-5-aminolaevulinate cream and placebo

Thomas Dirschka, Peter Radny, R. Dominicus et al. · British Journal of Dermatology · 2011 · 181 citations

Medicine, Dermatology, Pharmacology +15

Photodynamic therapy with BF-200 ALA for the treatment of actinic keratosis: results of a prospective, randomized, double-blind, placebo-controlled phase III study

Rolf‐Markus Szeimies, Peter Radny, Michael Sebastian et al. · British Journal of Dermatology · 2010 · 125 citations

Medicine, Dermatology, Ophthalmology +8

Long‐term (6 and 12 months) follow‐up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF‐200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis

Thomas Dirschka, Peter Radny, R. Dominicus et al. · British Journal of Dermatology · 2012 · 102 citations · Full text

Medicine, Dermatology, Ophthalmology +14

Patient‐reported health outcomes in patients with non‐melanoma skin cancer and actinic keratosis: results from a large‐scale observational study analysing effects of diagnoses and disease progression

Wolfgang G. Philipp‐Dormston, Karolina Müller, B. Novak et al. · Journal of the European Academy of Dermatology and Venereology · 2017 · 37 citations · Full text

Medicine, Dermatology, Oncology +16

Methyl aminolevulinate daylight photodynamic therapy applied at home for non‐hyperkeratotic actinic keratosis of the face or scalp: an open, interventional study conducted in Germany

Sigrid Karrer, Roland Aschoff, R. Dominicus et al. · Journal of the European Academy of Dermatology and Venereology · 2019 · 27 citations

Medicine, Dermatology, Ophthalmology +14